Breaking News
- Teva to Acquire CoGenesys
- Vegenics Licenses From CoGenesys Antibodies Against VEGF-C for Applications Including Oncology
Interested in partnering with CoGenesys?
Click here.
CoGenesys has established a robust drug pipeline through internal discovery capabilities and application of our albumin fusion technology platform and novel antibody targets.
The CoGenesys Product Pipeline
| Product Candidate | Indication | Status |
| Neugranin | Neutropenia | Phase 2 |
| Cardeva | Heart Failure | Phase 1/2a |
| CG209-Mab (Novel TNF family member) | Crohn's Disease, Psoriasis, Rheumatoid Arthritis | Pre-Clinical |
| Albu-Interferon Beta (b- Interferon) | Multiple Sclerosis | Pre-Clinical |
| Albulin-G (Insulin) | Type 1 & 2 Diabetes | Pre-Clinical |
